There were 1,481 press releases posted in the last 24 hours and 433,016 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image